Search

Your search keyword '"Wells, A.U."' showing total 134 results
Start Over Author "Wells, A.U."
134 results on '"Wells, A.U."'

1. Classification of Patients With Idiopathic Pulmonary Fibrosis According to Blood Biomarker Signatures by Consensus Cluster Analysis: A Multiple Machine Learning Approach

Author

Fainberg, H., primary, Moodley, Y.P., additional, Triguero, I., additional, Corte, T., additional, Sand, J.M.B., additional, Leeming, D.J., additional, Karsdal, M., additional, Renzoni, E., additional, Wells, A.U., additional, Fahy, W., additional, Oballa, E., additional, Porte, J., additional, Saini, G., additional, Johnson, S., additional, Wain, L., additional, Molyneaux, P.L., additional, Maher, T., additional, Stewart, I., additional, and Jenkins, G., additional

Published
2024
Full Text
View/download PDF

2. Using Imaging to Predict, Identify, and Monitor Progression of Interstitial Lung Disease: Consensus Findings From a Modified Delphi Study

Author

Walsh, S., primary, Wells, A.U., additional, Brown, K.K., additional, Adegunsoye, A., additional, Cottin, V., additional, Danoff, S., additional, Flaherty, K.R., additional, George, P.M., additional, Johannson, K.A., additional, Kolb, M., additional, Kondoh, Y., additional, Nicholson, A.G., additional, Tomassetti, S., additional, Volkmann, E.R., additional, and Devaraj, A., additional

Published
2024
Full Text
View/download PDF

3. Artificial Intelligence-based Decision Support for HRCT Stratification in Fibrotic Lung Disease: An International Study of 195 Observers From 43 Countries

Author

Walsh, S.L.F., primary, Wells, A.U., additional, Calandriello, L., additional, Felder, F., additional, Mackintosh, J., additional, Glaspole, I., additional, Goh, N., additional, Grainge, C., additional, Hopkins, P., additional, Moodley, Y.P., additional, Vidya, N., additional, Reynolds, P.N., additional, and Corte, T.J., additional

Published
2024
Full Text
View/download PDF

5. How Should Patients With Progressive Pulmonary Fibrosis Be Identified? Consensus Findings From a Modified Delphi Study

Author

Wells, A.U., primary, Walsh, S.L.F., additional, Adegunsoye, A., additional, Cottin, V., additional, Danoff, S., additional, Devaraj, A., additional, Flaherty, K.R., additional, George, P.M., additional, Johannson, K.A., additional, Kolb, M., additional, Kondoh, Y., additional, Nicholson, A.G., additional, Tomassetti, S., additional, Volkmann, E.R., additional, and Brown, K.K., additional

Published
2024
Full Text
View/download PDF

16. Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Study in Europe

Author

Karampitsakos, T., primary, Spagnolo, P., additional, Mogulkoc, N., additional, Wuyts, W.A., additional, Tomassetti, S., additional, Bendstrup, E., additional, Molina Molina, M., additional, Manali, E., additional, Unat, O.S., additional, Kahn, N., additional, Kolilekas, L., additional, Rosi, E., additional, Gori, L., additional, Ravaglia, C., additional, Daniil, Z., additional, Prior, T.S., additional, Papanikolaou, I.C., additional, Aso, S., additional, Tryfon, S., additional, Papakosta, D., additional, Balestro, E., additional, Papiris, S., additional, Antoniou, K., additional, Bouros, D.E., additional, Wells, A.U., additional, Kreuter, M., additional, and Tzouvelekis, A.E., additional

Published
2022
Full Text
View/download PDF

17. Evaluation of Change in Upper Lung Zone Radiologic Pleuroparenchymal Fibroelastosis (PPFE) as a Predictor of Mortality in Idiopathic Pulmonary Fibrosis (IPF)

Author

Chapman, R., primary, Gudmundsson, E., additional, Zhao, A., additional, Mogulkoc, N., additional, Stewart, I., additional, Jones, M.G., additional, van Moorsel, C.H.M., additional, Savas, R., additional, Brereton, C.J., additional, van Es, H.W., additional, Ezircan, A., additional, Pontoppidan, K., additional, van Beek, F., additional, Veltkamp, M., additional, Gholipour, B., additional, Wells, A.U., additional, Janes, S.M., additional, Alexander, D.C., additional, and Jacob, J., additional

Published
2022
Full Text
View/download PDF

18. Analysis of Forced Vital Capacity (FVC) Trajectories in Idiopathic Pulmonary Fibrosis (IPF) Identifies Four Distinct Clusters of Disease Behaviour

Author

Fainberg, H., primary, Allen, R., additional, Kraven, L., additional, Molyneaux, P.L., additional, Oldham, J., additional, Fahy, W., additional, Porte, J., additional, Saini, G., additional, Karsdal, M., additional, Leeming, D.J., additional, Triguero, I., additional, Oballa, E., additional, Noth, I., additional, Wells, A.U., additional, Renzoni, E., additional, Maher, T., additional, Wain, L.V., additional, Stewart, I., additional, and Jenkins, J., additional

Published
2022
Full Text
View/download PDF

21. Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Multi-Centre Randomised Controlled Trial

Author

Maher, T.M., primary, Tudor, V., additional, Saunders, P., additional, Gibbons, M., additional, Fletcher, S., additional, Parfrey, H., additional, Denton, C.P., additional, Renzoni, E., additional, Kokosi, M., additional, Wells, A.U., additional, Ashby, D., additional, Szigeti, M., additional, and Molyneaux, P.L., additional

Published
2022
Full Text
View/download PDF

22. Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Author

Behr, J. Nathan, S.D. Wuyts, W.A. Mogulkoc Bishop, N. Bouros, D.E. Antoniou, K. Guiot, J. Kramer, M.R. Kirchgaessler, K.-U. Bengus, M. Gilberg, F. Perjesi, A. Harari, S. Wells, A.U.

Abstract

Background: The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already present or likely to develop, is uncertain. We aimed to assess the efficacy and safety of sildenafil added to pirfenidone versus placebo added to pirfenidone for 52 weeks in patients with advanced IPF and at risk of group 3 pulmonary hypertension. Methods: We did a multicentre, international, double-blind, randomised, placebo-controlled, phase 2b study at 56 university clinics, research hospitals, and tertiary sites in Canada, Europe (Belgium, Czech Republic, Germany, Greece, Hungary, Italy, the Netherlands, Spain, and Turkey), Israel, and Africa (Egypt and South Africa). Eligible patients (aged 40–80 years) had advanced IPF (carbon monoxide diffusing capacity ≤40% predicted at screening), and were at risk of group 3 pulmonary hypertension (mean pulmonary artery pressure of ≥20 mm Hg with pulmonary artery wedge pressure of ≤15 mm Hg on previous right-heart catheterisation, or intermediate or high probability of group 3 pulmonary hypertension on echocardiography as defined by the 2015 European Society of Cardiology and European Respiratory Society guidelines). Patients were randomly assigned 1:1 to oral sildenafil tablets (20 mg three times daily) or placebo, both in addition to oral pirfenidone capsules (801 mg three times daily), using a validated interactive voice-based or web-based response system with permuted block randomisation, stratified by previous right-heart catheterisation (yes or no) and forced expiratory volume in 1 s to forced vital capacity ratio (

Published
2021

32. Efficacy and Safety of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Pulmonary Hypertension (PH)

Author

Behr, J., primary, Nathan, S.D., additional, Harari, S., additional, Wuyts, W., additional, Mogulkoc, N., additional, Bouros, D.E., additional, Antoniou, K., additional, Guiot, J., additional, Kramer, M.R., additional, Kirchgaessler, K.-U., additional, Bengus, M., additional, Gilberg, F., additional, Perjesi, A., additional, and Wells, A.U., additional

Published
2020
Full Text
View/download PDF

39. The Six-Minute Walk Test in Sarcoidosis Associated Pulmonary Hypertension: Results from an International Registry

Author

Gupta, R., primary, Baughman, R.P., additional, Nathan, S.D., additional, Wells, A.U., additional, Kouranos, V., additional, Alhamad, E.H., additional, Culver, D.A., additional, Barney, J., additional, Carmona Porquera, E.M., additional, Huitema, M., additional, Scholand, M.B., additional, Wijsenbeek, M., additional, Ganesh, S., additional, Birring, S.S., additional, and Shlobin, O.A., additional

Published
2020
Full Text
View/download PDF

42. The Role of Chest Imaging in Patient Management During the COVID-19 Pandemic A Multinational Consensus Statement From the Fleischner Society

Author

Rubin, G.D., Ryerson, C.J., Haramati, L.B., Sverzellati, Nicola, Kanne, J.P., Raoof, S., Prokop, M., Schaefer-Prokop, C.M., Wells, A.U., and Leung, A.N.C.

Subjects
All institutes and research themes of the Radboud University Medical Center, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Contains fulltext : 221588.pdf (Publisher’s version ) (Closed access)

Published
2020

43. Nintedanib in patients with progressive fibrosing interstitial lung diseases - subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Author

Wells, A.U., Flaherty, K.R., Brown, K.K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W.A., Stowasser, S., Quaresma, M., Goeldner, R.-G., Schlenker-Herceg, R., Kolb, M., Abe, S., Aburto, M., Acosta, O., Andrews, C., Antin-Ozerkis, D., Arce, G., Arias, M., Avdeev, S., Barczyk, A., Bascom, R., Bazdyrev, E., Beirne, P., Belloli, E., Bergna, M.A., Bergot, E., Bhatt, N., and Publica

Abstract

Background: The INBUILD trial investigated the efficacy and safety of nintedanib versus placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF). We aimed to establish the effects of nintedanib in subgroups based on ILD diagnosis. Methods: The INBUILD trial was a randomised, double-blind, placebo-controlled, parallel group trial done at 153 sites in 15 countries. Participants had an investigator-diagnosed fibrosing ILD other than IPF, with chest imaging features of fibrosis of more than 10% extent on high resolution CT (HRCT), forced vital capacity (FVC) of 45% or more predicted, and diffusing capacity of the lung for carbon monoxide (DLco) of at least 30% and less than 80% predicted. Participants fulfilled protocol-defined criteria for ILD progression in the 24 months before screening, despite management considered appropriate in clinical practice for the individual ILD. Participants were randomly assigned 1:1 by means of a pseudo-random number generator to receive nintedanib 150 mg twice daily or placebo for at least 52 weeks. Participants, investigators, and other personnel involved in the trial and analysis were masked to treatment assignment until after database lock. In this subgroup analysis, we assessed the rate of decline in FVC (mL/year) over 52 weeks in patients who received at least one dose of nintedanib or placebo in five prespecified subgroups based on the ILD diagnoses documented by the investigators: hypersensitivity pneumonitis, autoimmune ILDs, idiopathic non-specific interstitial pneumonia, unclassifiable idiopathic interstitial pneumonia, and other ILDs. The trial has been completed and is registered with ClinicalTrials.gov, number NCT02999178. Findings: Participants were recruited between Feb 23, 2017, and April 27, 2018. Of 663 participants who received at least one dose of nintedanib or placebo, 173 (26%) had chronic hypersensitivity pneumonitis, 170 (26%) an autoimmune ILD, 125 (19%) idiopathic non-specific interstitial pneumonia, 114 (17%) unclassifiable idiopathic interstitial pneumonia, and 81 (12%) other ILDs. The effect of nintedanib versus placebo on reducing the rate of FVC decline (mL/year) was consistent across the five subgroups by ILD diagnosis in the overall population (hypersensitivity pneumonitis 73·1 [95% CI −8·6 to 154·8]; autoimmune ILDs 104·0 [21·1 to 186·9]; idiopathic non-specific interstitial pneumonia 141·6 [46·0 to 237·2]; unclassifiable idiopathic interstitial pneumonia 68·3 [−31·4 to 168·1]; and other ILDs 197·1 [77·6 to 316·7]; p=0·41 for treatment by subgroup by time interaction). Adverse events reported in the subgroups were consistent with those reported in the overall population. Interpretation: The INBUILD trial was not designed or powered to provide evidence for a benefit of nintedanib in specific diagnostic subgroups. However, its results suggest that nintedanib reduces the rate of ILD progression, as measured by FVC decline, in patients who have a chronic fibrosing ILD and progressive phenotype, irrespective of the underlying ILD diagnosis. Funding: Boehringer Ingelheim.

Published
2020

49. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test

Author

Buch, M.H., Denton, C.P., Furst, D.E., Guillevin, L., Rubin, L.J., Wells, A.U., Matucci-Cerinic, M., Riemekasten, G., Emery, P., Chadha-Boreham, H., Charef, P., Roux, S., Black, C.M., and Seibold, J.R.

Subjects
Lung diseases, Interstitial -- Patient outcomes, Lung diseases, Interstitial -- Research, Exercise tests -- Analysis, Health
Published
2007

50. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry

Author

Shlobin, O.A. (Oksana A.), Kouranos, V. (Vasilis), Barnett, S.D. (Scott D.), Alhamad, E.H. (Esam H.), Culver, D.A. (Daniel), Barney, J. (Joseph), Cordova, F.C. (Francis C.), Carmona, E.M. (Eva M.), Scholand, M.B. (Mary Beth), Wijsenbeek-Lourens, M.S. (Marlies), Ganesh, S. (Sivagini), Lower, E.E. (Elyse E.), Engel, P.J. (Peter J.), Wort, J. (John), Price, L. (Laura), Wells, A.U. (Athol U.), Nathan, S.D. (Steven D.), Baughman, R.P. (Robert), Shlobin, O.A. (Oksana A.), Kouranos, V. (Vasilis), Barnett, S.D. (Scott D.), Alhamad, E.H. (Esam H.), Culver, D.A. (Daniel), Barney, J. (Joseph), Cordova, F.C. (Francis C.), Carmona, E.M. (Eva M.), Scholand, M.B. (Mary Beth), Wijsenbeek-Lourens, M.S. (Marlies), Ganesh, S. (Sivagini), Lower, E.E. (Elyse E.), Engel, P.J. (Peter J.), Wort, J. (John), Price, L. (Laura), Wells, A.U. (Athol U.), Nathan, S.D. (Steven D.), and Baughman, R.P. (Robert)

Abstract

INTRODUCTION: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with reduced survival in single-centre studies. The international Registry for SAPH (ReSAPH) with long-term follow-up was established to enrich our knowledge of this complication of sarcoidosis. This analysis aims to elucidate factors associated with reduced transplant-free survival in SAPH patients. METHODS: ReSAPH contains prospectively collected outcomes of SAPH patients since the time of registry enrolment. Information analysed includes right heart catheterisation data, pulmonary function testing, chest radiography, Scadding stage and 6-min walk distance (6MWD), among others. Cox regression models were used to identify independent predictors of transplant-free survival. RESULTS: Data from 215 patients followed for a mean±sd 2.5±1.9 years were available for analysis. In the 159 precapillary patients, the Kaplan-Meier-adjusted 1-, 3- and 5-year transplant-free survival was 89.2%, 71.7% and 62.0%, respectively. Kaplan-Meier-adjusted 1-, 3- and 5-year transplant-free survival in the incident group was 83.5%, 70.3% and 58.3%, respectively, and in the prevalent group was 94.7%, 72.2% and 66.3%, respectively. Patients with reduced diffusing capacity of the lung for carbon monoxide (DLCO) (<35% predicted) and 6MWD <300 m in the precapillary cohort had significantly worse transplant-free survival. Reduced 6MWD and preserved forced expiratory volume (FEV1)/forced vital capacity (FVC) ratio were identified as independent risk factors for reduced transplant-free survival in the precapillary cohort. CONCLUSION: Reduced DLCO (<35% pred) and 6MWD (<300 m) at the time of registry enrolment were associated with reduced transplant-free surviv

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results